MAPK14 and chronic obstructive pulmonary disease: p38 MAP kinase inhibitors have been under the clinical trials for cardiovascular disease and chronic obstructive lung disease, and one of p38 MAP kinase inhibitors demonstrated significant anti-inflammatory effects by ameliorating disease biomarkers [47], [48].